Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose in iron-deficient idiopathic pulmonary arterial hypertension
2010-024585-22Phase 2Terminated
- Sponsor
- Imperial College Academic Health Sciences Centre
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ferric carboxymaltose in Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH) and iron deficiency anemia (IDA), sponsored by Imperial College Academic Health Sciences Centre. Primary endpoint: Change in resting pulmonary vascular resistance. Started Feb 2011; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2010-024585-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024585-22.